The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

M Dyer; C Hutchinson; S Rule; N Shah; GA Salles; L Karlin; F Morschhauser; L Terriou; C Fegan; A Davison; G Cartron; A Saunders; H Honda; J Sharpe; T Yoshizawa; T Yasuhiro; K Kawabata; H Awata; J Birkett

doi:10.1200/jco.2014.32.15_suppl.8553

The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

M Dyer, C Hutchinson, S Rule, N Shah, GA Salles, L Karlin, F Morschhauser, L Terriou, C Fegan, A Davison, G Cartron, A Saunders, H Honda, J Sharpe, T Yoshizawa, T Yasuhiro, K Kawabata, H Awata, J Birkett

Peninsula Medical School

Research output: Contribution to journal › Conference proceedings published in a journal › peer-review

Original language	English
Pages (from-to)	8553-8553
Number of pages	0
Journal	Journal of Clinical Oncology
Volume	32
Issue number	0
DOIs	https://doi.org/10.1200/jco.2014.32.15_suppl.8553
Publication status	Published - 20 May 2014

Access to Document

10.1200/jco.2014.32.15_suppl.8553

Cite this

Dyer, M., Hutchinson, C., Rule, S., Shah, N., Salles, GA., Karlin, L., Morschhauser, F., Terriou, L., Fegan, C., Davison, A., Cartron, G., Saunders, A., Honda, H., Sharpe, J., Yoshizawa, T., Yasuhiro, T., Kawabata, K., Awata, H., & Birkett, J. (2014). The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL. Journal of Clinical Oncology, 32(0), 8553-8553. https://doi.org/10.1200/jco.2014.32.15_suppl.8553

@article{e4c33165e224411ab879eeb0dc2354d4,

title = "The Bruton{\textquoteright}s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.",

author = "M Dyer and C Hutchinson and S Rule and N Shah and GA Salles and L Karlin and F Morschhauser and L Terriou and C Fegan and A Davison and G Cartron and A Saunders and H Honda and J Sharpe and T Yoshizawa and T Yasuhiro and K Kawabata and H Awata and J Birkett",

year = "2014",

month = may,

day = "20",

doi = "10.1200/jco.2014.32.15_suppl.8553",

language = "English",

volume = "32",

pages = "8553--8553",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "0",

}

Dyer, M, Hutchinson, C, Rule, S, Shah, N, Salles, GA, Karlin, L, Morschhauser, F, Terriou, L, Fegan, C, Davison, A, Cartron, G, Saunders, A, Honda, H, Sharpe, J, Yoshizawa, T, Yasuhiro, T, Kawabata, K, Awata, H & Birkett, J 2014, 'The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.', Journal of Clinical Oncology, vol. 32, no. 0, pp. 8553-8553. https://doi.org/10.1200/jco.2014.32.15_suppl.8553

TY - JOUR

T1 - The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

AU - Dyer, M

AU - Hutchinson, C

AU - Rule, S

AU - Shah, N

AU - Salles, GA

AU - Karlin, L

AU - Morschhauser, F

AU - Terriou, L

AU - Fegan, C

AU - Davison, A

AU - Cartron, G

AU - Saunders, A

AU - Honda, H

AU - Sharpe, J

AU - Yoshizawa, T

AU - Yasuhiro, T

AU - Kawabata, K

AU - Awata, H

AU - Birkett, J

PY - 2014/5/20

Y1 - 2014/5/20

U2 - 10.1200/jco.2014.32.15_suppl.8553

DO - 10.1200/jco.2014.32.15_suppl.8553

M3 - Conference proceedings published in a journal

SN - 0732-183X

VL - 32

SP - 8553

EP - 8553

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 0

ER -